Hit enter to search or ESC to close
Hepion PharmaceuticalsHepion Pharmaceuticals
  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers
Hepion Pharmaceuticals

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH [BioTuesdays]

By HepionNovember 11, 2020December 2nd, 2020Media Placements
No Comments

Hepion Pharmaceuticals employing artificial intelligence to tackle NASH [BioTuesdays]

https://hepionpharma.com/wp-content/uploads/2020/11/BioTuesdays-November-2020.pdf
Hepion Pharmaceuticals, Inc. Announces Closing of Public Offering
February 18, 2021

Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021

Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
February 12, 2021

Share Tweet Share Pin
Get Important News and Updates by Email Subscribe

© 2021 Hepion Pharmaceuticals | Disclaimer & Terms of Use | WDDI

  • About
    • Company Overview
    • Executive Team
    • Cyclophilin Expertise
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Liver Disease
    • Overview
    • Non-alcoholic Steatohepatitis (NASH)
    • Hepatocellular Carcinoma (HCC)
    • Viral Hepatitis
  • AI-POWR™
  • Pipeline
    • Overview
    • CRV431
    • Therapeutic Strategy
    • Clinical Trials
    • Publications
  • Newsroom
  • Investors
    • Investor Overview
    • Press Releases
    • Events
    • Presentations
    • Company Information
    • Stock Information
    • SEC Filings
    • Corporate Governance
  • Contact
    • Contact Us
    • Careers